Jonas H A, Newman J D, Harrison L C
Proc Natl Acad Sci U S A. 1986 Jun;83(12):4124-8. doi: 10.1073/pnas.83.12.4124.
Insulin receptors purified from human placenta by sequential affinity chromatography on wheat germ lectin-agarose and insulin coupled to 1,1'-carbonyldiimidazole-activated agarose (CDI-agarose) retained full binding activity but bound a greater than predicted amount of 125I-labeled insulin-like growth factor I (IGF-I). IGF-I and multiplication-stimulating activity (MSA; the rat homologue of IGF-II) were equipotent in displacing either 125I-labeled IGF-I or 125I-labeled MSA from the purified receptors; insulin was 5-15 times more potent. Competitive binding studies indicated that this IGF binding activity could not be explained by cross-reaction with classical insulin receptors or by coelution of IGF-I or IGF-II receptors. Instead, it was due to a minor population of discrete atypical insulin receptors (6-18% total insulin receptors) with moderately high affinity (Kd = 2-4 X 10(-9) M) for IGF-I and MSA. These receptors were not an artifact of insulin-CDI-agarose chromatography, since they were present in wheat germ lectin-agarose-purified preparations and could also be purified from insulin-succinyldiaminodipropylamino-agarose. Affinity labeling with 125I-labeled MSA revealed that these atypical receptors had the same binding subunit (Mr 140,000) as classical insulin and IGF-I receptors. They displayed intermediate reactivity with polyclonal and monoclonal antibodies to the insulin and IGF-I receptors. It is therefore likely that insulin receptors purified by immunoadsorption would also contain atypical insulin receptors. The finding of more than one type of insulin receptor might relate to the slight variations in the cDNA nucleotide sequences and the multiple mRNA species reported for the insulin receptor [Ebina, Y., Ellis, L., Jarnagin, K., Edery, M., Graf, L., Clauser, E., Ou, J.-H., Masiarz, F., Kan, Y. W., Goldfine, I. D., Roth, R. A. & Rutter, W. J. (1985) Cell 40, 747-758].
通过在麦胚凝集素 - 琼脂糖和与1,1'-羰基二咪唑活化琼脂糖(CDI - 琼脂糖)偶联的胰岛素上进行连续亲和层析从人胎盘中纯化得到的胰岛素受体保留了完全的结合活性,但结合的125I标记的胰岛素样生长因子I(IGF - I)量大于预期。IGF - I和增殖刺激活性(MSA;IGF - II的大鼠同源物)在从纯化的受体上置换125I标记的IGF - I或125I标记的MSA方面具有同等效力;胰岛素的效力高5 - 15倍。竞争性结合研究表明,这种IGF结合活性不能用与经典胰岛素受体的交叉反应或IGF - I或IGF - II受体的共洗脱来解释。相反,它是由于一小部分离散的非典型胰岛素受体(占总胰岛素受体的6 - 18%)对IGF - I和MSA具有中等高度亲和力(Kd = 2 - 4×10(-9) M)。这些受体不是胰岛素 - CDI - 琼脂糖层析的假象,因为它们存在于麦胚凝集素 - 琼脂糖纯化的制剂中,也可以从胰岛素 - 琥珀酰二氨基二丙基氨基 - 琼脂糖中纯化得到。用125I标记的MSA进行亲和标记显示,这些非典型受体与经典胰岛素和IGF - I受体具有相同的结合亚基(Mr 140,000)。它们与针对胰岛素和IGF - I受体的多克隆和单克隆抗体表现出中等反应性。因此,通过免疫吸附纯化的胰岛素受体可能也含有非典型胰岛素受体。发现不止一种类型的胰岛素受体可能与胰岛素受体报道的cDNA核苷酸序列的轻微变化和多种mRNA种类有关[Ebina, Y., Ellis, L., Jarnagin, K., Edery, M., Graf, L., Clauser, E., Ou, J.-H., Masiarz, F., Kan, Y. W., Goldfine, I. D., Roth, R. A. & Rutter, W. J. (1985) Cell 40, 747 - 758]。